文献速递肺结节与肺癌

Lurbinectedin联合多柔比星对比医师选择化疗用于复发小细胞肺癌(ATLANTIS):多中心随机开放标签3期试验

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2022-10-14

ATLANTIS研究在北美、南美、欧洲和中东135家医院入组613例铂类化疗后复发的成人小细胞肺癌患者,1:1随机接受lurbinectedin联合多柔比星或医师选择化疗(拓扑替康或CAV)。联合组3级及以上血液学不良事件更少。

要点

  • 联合组3级及以上贫血、中性粒细胞减少和血小板减少发生率均低于对照组。
  • 联合组因治疗相关不良事件停药比例9%,低于对照组的16%。

核心结论

  • 在铂类治疗后复发的SCLC患者中,lurbinectedin联合多柔比星较对照化疗未改善总生存期。
  • 联合方案较对照方案显示出更有利的血液学安全性特征。

研究设计与样本

  • 3期、开放标签、随机、多中心研究,纳入18岁及以上铂类化疗后复发的SCLC患者。
  • 2016年8月30日至2018年8月20日从北美、南美、欧洲和中东135家医院入组,613例患者1:1随机分配。
  • 主要终点为意向治疗人群的总生存期;两组均强制进行G-CSF一级预防;独立评审委员会设盲。
  • 安全性在至少接受部分或完整研究治疗输注的患者中评估(联合组303例,对照组289例)。

主要发现

  • 治疗相关不良事件导致死亡者联合组2例(<1%,共303例)、对照组10例(3%,共289例)。
  • 治疗中出现的不良事件联合组296/303例(98%)、对照组284/289例(98%);治疗相关不良事件分别为268/303例(88%)和266/289例(92%)。
  • 3级及以上贫血联合组57/302例(19%)vs对照组110/288例(38%),中性粒细胞减少112例(37%)vs 200例(69%),血小板减少42例(14%)vs 90例(31%);因治疗相关不良事件停药26/303例(9%)vs 47/289例(16%)。

关键数值与推荐

  • 两组均强制进行G-CSF一级预防。

临床怎么用

  • 对于铂类化疗后复发的SCLC,lurbinectedin联合多柔比星不应以改善生存为目的替代对照化疗。
  • 联合方案的血液学毒性负担较低,可在需要控制血液学毒性时作为个体化考虑。
  • 治疗决策应结合患者血液学耐受性与既往治疗情况综合评估。

局限性

  • 研究为开放标签设计,患者和临床医生未设盲(独立评审委员会设盲)。
  • 对照组包含拓扑替康或CAV两种医师选择方案,非单一对照。
  • 未报告联合方案组内与对照各亚组间的疗效比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin as second-line treatment for SCLC. METHODS: In this phase 3, open-label, randomised study, adult patients aged 18 years or older with SCLC who relapsed after platinum-based chemotherapy were recruited from 135 hospitals across North America, South America, Europe, and the Middle East. Patients were randomly assigned (1:1) centrally by dynamic allocation to intravenous lurbinectedin 2·0 mg/m2 plus doxorubicin 40·0 mg/m2 administered on day 1 of 21-day cycles or physician's choice of control therapy (intravenous topotecan 1·5 mg/m2 on days 1-5 of 21-day cycles; or intravenous cyclophosphamide 1000 mg/m2, doxorubicin 45·0 mg/m2, and vincristine 2·0 mg on day 1 of 21-day cycles [CAV]) administered until disease progression or unacceptable toxicity. Primary granulocyte-colony stimulating factor prophylaxis was mandatory in both treatment groups. Neither patients nor clinicians were masked to treatment allocation, but the independent review committee, which assessed outcomes, was masked to patients' treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02566993, and with EudraCT, 2015-001641-89, and is complete. FINDINGS: Between Aug 30, 2016, and Aug 20, 2018, 613 patients were randomly assigned to lurbinectedin plus doxorubicin (n=307) or control (topotecan, n=127; CAV, n=179) and comprised the intention-to-treat population; safety endpoints were assessed in patients who had received any partial or complete study treatment infusions (lurbinectedin plus doxorubicin, n=303; control, n=289). After a median follow-up of 24·1 months (95% CI 21·7-26·3), 303 patients in the lurbinectedin plus doxorubicin group and 289 patients in the control group had discontinued study treatment; progressive disease was the most common reason for discontinuation (213 [70%] patients in the lurbinectedin plus doxorubicin group vs 152 [53%] in the control group). Median overall survival was 8·6 months (95% CI 7·1-9·4) in the lurbinectedin plus doxorubicin group versus 7·6 months (6·6-8·2) in the control group (stratified log-rank p=0·90; hazard ratio 0·97 [95% CI 0·82-1·15], p=0·70). 12 patients died because of treatment-related adverse events: two (<1%) of 303 in the lurbinectedin plus doxorubicin group and ten (3%) of 289 in the control group. 296 (98%) of 303 patients in the lurbinectedin plus doxorubicin group had treatment-emergent adverse events compared with 284 (98%) of 289 patients in the control group; treatment-related adverse events occurred in 268 (88%) patients in the lurbinectedin plus doxorubicin group and 266 (92%) patients in the control group. Grade 3 or worse haematological adverse events were less frequent in the lurbinectedin plus doxorubicin group than the control group (anaemia, 57 [19%] of 302 patients in the lurbinectedin plus doxorubicin group vs 110 [38%] of 288 in the control group; neutropenia, 112 [37%] vs 200 [69%]; thrombocytopenia, 42 [14%] vs 90 [31%]). The frequency of treatment-related adverse events leading to treatment discontinuation was lower in the lurbinectedin plus doxorubicin group than in the control group (26 [9%] of 303 patients in the lurbinectedin plus doxorubicin group vs 47 [16%] of 289 in the control group). INTERPRETATION: Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control. FUNDING: PharmaMar.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Aix SP, Ciuleanu TE, Navarro A, et al. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2022. PMID: 36252599. doi:10.1016/S2213-2600(22)00309-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。